Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

Neuropharmacology

Volumn 48, Issue 4, 2005, Pages 503-516

  Hallett, P J ^a   Dunah, A W ^a   Ravenscroft, P ^b   Zhou, S ^b   Bezard, E ^c   Crossman, A R ^b   Brotchie, J M ^d   Standaert, D G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Basal ganglia; Dopamine; Glutamate; Levodopa; Macaque; Trafficking

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN SYNAPTOSOME; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE MODEL; DYSKINESIA; FEMALE; IMMUNOBLOTTING; MACACA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR INTRINSIC ACTIVITY; SYNAPTIC MEMBRANE;

EID: 14744290753     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.11.008     Document Type: Article

References (48)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458
2. M.K. Bennett, N. Calakos, and R.H. Scheller Syntaxin: a synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones Science 257 1992 255 259
3. R. Betarbet, O. Poisik, T.B. Sherer, and J.T. Greenamyre Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease Exp. Neurol. 187 2004 76 85
4. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev. Neurosci. 2 2001 577 588
5. E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, D. Guilloteau, A.R. Crossman, B. Bioulac, J.M. Brotchie, and C.E. Gross Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned macaque model of Parkinson's disease J. Neurosci. 21 2001 6853 6861
6. P.J. Blanchet, S. Konitsiotis, E.R. Whittemore, Z.L. Zhou, R.M. Woodward, and T.N. Chase Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys J. Pharmacol. Exp. Ther. 290 1999 1034 1040
7. J.P. Bolam, J.J. Hanley, P.A. Booth, and M.D. Bevan Synaptic organisation of the basal ganglia J. Anat. 196 Pt 4 2000 527 542
8. P. Calabresi, A. Pisani, N.B. Mercuri, and G. Bernardi Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels Eur. J. Neurosci. 4 1992 929 935
9. F. Calon, M. Morissette, O. Ghribi, M. Goulet, R. Grondin, P.J. Blanchet, P.J. Bedard, and P.T. Di Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 127 138
10. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bedard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416
11. T.N. Chase, and J.D. Oh Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci. 23 2000 S86 S91
12. T.N. Chase, and J.D. Oh Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann. Neurol. 47 2000 S122 S129
13. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene Modification of parkinsonism-chronic treatment with L-DOPA N. Engl. J. Med. 280 1969 337 345
14. V. David, F. Hochstenbach, S. Rajagopalan, and M.B. Brenner Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin) J. Biol. Chem. 268 1993 9585 9592
15. G. Di Chiara, M. Morelli, and S. Consolo Modulatory functions of neurotransmitters in the striatum - ACh/dopamine/NMDA interactions Trends Neurosci. 17 1994 228 233
16. R. Dingledine, K. Borges, D. Bowie, and S.F. Traynelis The glutamate receptor ion channels Pharmacol. Rev. 51 1999 7 61
17. A.W. Dunah, A.C. Sirianni, A.A. Fienberg, E. Bastia, M.A. Schwarzschild, and D.G. Standaert Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32 Mol. Pharmacol. 65 2004 121 129
18. A.W. Dunah, and D.G. Standaert Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane J. Neurosci. 21 2001 5546 5558
19. A.W. Dunah, and D.G. Standaert Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum J. Neurochem. 85 2003 935 943
20. A.W. Dunah, Y.H. Wang, R.P. Yasuda, K. Kameyama, R.L. Huganir, B.B. Wolfe, and D.G. Standaert Alterations in subunit expression, composition and phosphorylation of striatal NMDA glutamate receptors in the rat 6-OHDA models of Parkinson's disease Mol. Pharmacol. 57 2000 342 352
21. S. Fahn Parkinson disease, the effect of levodopa, and the ELLDOPA trial. earlier vs later L-DOPA Arch. Neurol. 56 1999 529 535
22. D. Guilloteau, P. Emond, J.L. Baulieu, L. Garreau, Y. Frangin, L. Pourcelot, L. Mauclaire, J.C. Besnard, and S. Chalon Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2- β-carbomethoxy-3-β-(4′-methylphenyl) nortropane (PE2I) Nucl. Med. Biol. 25 1998 331 337
23. A. Hadj Tahar, L. Gregoire, A. Darre, N. Belanger, L. Meltzer, and P.J. Bedard Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys Neurobiol. Dis. 15 2004 171 176
24. Hallett, P.J., Dunah, A.W., Ravenscroft, P., Zhou, S., Bezard E., Crossman, A.R., Brotchie, J.M., Standaert, D.G., 2003. Striatal NMDA receptor subunit abundance and phosphorylation in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. 2003 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC (online program 946.7).
25. P.J. Hallett, and D.G. Standaert Rationale for and use of NMDA receptor antagonists in Parkinson's disease Pharmacol. Ther. 102 2004 155 174
26. P. Jenner The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications Neurology 61 2003 S4 S11
27. T. Klockgether, and L. Turski Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia Ann. Neurol. 34 1993 585 593
28. H.C. Kornau, L.T. Schenker, M.B. Kennedy, and P.H. Seeburg Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95 Science 269 1995 1737 1740
29. C.M. Kosinski, D.G. Standaert, T.J. Counihan, C.R. Scherzer, J.A. Kerner, L.P. Daggett, G. Velicelebi, J.B. Penney, and A.B. Young Expression of N-methyl-d-aspartate receptor subunit mRNA in the human neostriatum and globus pallidus J. Comp. Neurol. 390 1998 63 74
30. K.D. Küppenbender, D.G. Standaert, T.J. Feuerstein, J.B. Penney Jr., A.B. Young, and G.B. Landwehrmeyer Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum J. Comp. Neurol. 419 2000 407 421
31. K.W. Lange, J. Kornhuber, and P. Riederer Dopamine/glutamate interactions in Parkinson's disease Neurosci. Biobehav. Rev. 21 1997 393 400
32. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
33. L.F. Lau, and R.L. Huganir Differential tyrosine phosphorylation of N-methyl-d-aspartate receptor subunits J. Biol. Chem. 270 1995 20036 20041
34. P.A. Loschmann, C. De Groote, L. Smith, U. Wullner, G. Fischer, J.A. Kemp, P. Jenner, and T. Klockgether Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease Exp. Neurol. 187 2004 86 93
35. J. Luo, Y. Wang, R.P. Yasuda, A.W. Dunah, and B.B. Wolfe The majority of N-methyl-d-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B) Mol. Pharmacol. 51 1997 79 86
36. M. Menegoz, L.F. Lau, D. Herve, R.L. Huganir, and J.A. Girault Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions Neuroreport 7 1995 125 128
37. J.E. Nash, S.H. Fox, B. Henry, M.P. Hill, D. Peggs, S. McGuire, Y. Maneuf, C. Hille, J.M. Brotchie, and A.R. Crossman Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease Exp. Neurol. 165 2000 136 142
38. J.E. Nash, M.P. Hill, and J.M. Brotchie Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat Exp. Neurol. 155 1998 42 48
39. J.D. Oh, D. Russell, C.L. Vaughan, and T.N. Chase Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration Brain Res. 813 1998 150 159
40. J.D. Oh, C.L. Vaughan, and T.N. Chase Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits Brain Res. 821 1999 433 442
41. S.M. Papa, and T.N. Chase Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys Ann. Neurol. 39 1996 574 578
42. B. Picconi, F. Gardoni, D. Centonze, D. Mauceri, M.A. Cenci, G. Bernadi, P. Calabresi, and M. Di Luca Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism J. Neurosci. 24 2004 5283 5291
43. M. Sheng, J. Cummings, L.A. Roldan, Y.N. Jan, and L.Y. Jan Changing subunit composition of heteromeric NMDA receptors during development Nature 368 1994 144 147
44. A.D. Smith, and J.P. Bolam The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones Trends Neurosci. 13 1990 259 265
45. D.G. Standaert, I.K. Friberg, G.B. Landwehrmeyer, A.B. Young, and J.B. Penney Jr. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat Brain. Res. Mol. Brain. Res. 64 1999 11 23
46. D.G. Standaert, C.M. Testa, J.B. Penney, and A.B. Young Organization of N-methyl-d-aspartate glutamate receptor gene expression in the basal ganglia of the rat J. Comp. Neurol. 343 1994 1 16
47. K. Steece-Collier, L.K. Chambers, S.S. Jaw-Tsai, F.S. Menniti, and J.T. Greenamyre Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors Exp. Neurol. 163 2000 239 243
48. R.H. Wessell, S.M. Ahmed, F.S. Menniti, G.L. Dunbar, T.N. Chase, and J.D. Oh NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations hemi-parkinsonian rats Neuropharmacology 47 2004 184 194